Day: October 3, 2025

OKOTOKS, Alberta, Oct. 03, 2025 (GLOBE NEWSWIRE) — (TSX: MTL) Mullen Group Ltd. (“Mullen Group” and/or the “Corporation“) intends to release its 2025 Third Quarter earnings results on Wednesday, October 22, 2025, at 6:00 a.m. ET, and has scheduled a conference call and webcast as follows:Date: October 22, 2025   Time: 10:00 a.m. ET   Pre-Registration: registration link     Upon registering, you will receive a calendar booking by email with dial in details and a unique PIN. This process will bypass the operator and avoid the queue. Registration will remain open until the end of the conference call.   Dial-in: 1-833-752-3592 (for participants in North America)  +1-647-846-8386 (International participants)   Webcast: www.mullen-group.com   Replay: Two weeks until November...

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal,1 demonstrating the pressure injury prevention mechanism of action of ALLEVYN COMPLETE CARE Foam Dressing and its ability to absorb and dissipate friction and shear forces. Pressure injuries are localized damage to the skin or underlying tissue, resulting from prolonged exposure to pressure in combination with shear forces.2 This landmark study demonstrates that the new ALLEVYN COMPLETE CARE Foam Dressing absorbs 93% of mechanical energy into its internal layers. The study shows that the dressing absorbs and dissipates shear forces internally and layer-to-layer frictional sliding within the dressing. This mechanism of action can significantly...

LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. CONTACT: Gary Owens, President and CEO, or John Sakys, CFO, both of Mesa Laboratories, Inc., +1-303-987-8000 For more information about the Mesa, please visit our website at www.mesalabs.com.

Ivry-sur-Seine – France, October 3, 2025 Regulated information INFORMATION ON THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers)Stock Market Euronext ParisISIN Code FR0011476928DateTotal number of shares composing the share capital of the company Total number of gross voting rightsTotal number of net voting rights (*)September 30, 2025 29,682,146 29,682,146 29,096,998(*) Net = After deduction of the shares deprived of voting right In accordance with Article 9 of the Company’s Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or indirectly,...

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) — Brandywine Realty Trust (the “Company”) (NYSE: BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has closed its previously announced underwritten public offering of $300 million of its 6.125% guaranteed notes due 2031 (the “Notes”). The Operating Partnership intends to use the net proceeds of the offering to repay its consolidated secured debt and for general corporate purposes, which may include the repayment, repurchase or other retirement of other indebtedness. The offering of the Notes was made pursuant to an effective shelf registration statement and related prospectus and preliminary prospectus supplement filed by the Company with the Securities and Exchange Commission. This press release shall not constitute...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577Date Total number of shares representing the share capital Total number of voting rightsSeptember, 30 2025 8 390 660 Gross total of voting rights : 12 705 441Net total* of voting rights : 12 692 605Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal healthNYSE Euronext – Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel. 33 4 92 08 71 32 / Email: finances@virbac.comWebsite:...

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) — In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common form of eczema. This recognition comes as the American Medical Association (AMA) has expanded excimer laser’s indications to inflammatory and autoimmune skin diseases, clearing the way for Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment. Dr. Dolev Rafeli, Strata’s CEO, stated, “Excimer laser...

TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (TSXV: QGR) (“Q-Gold” or the “Company”) is pleased to announce that it has closed its previously announced private placement offering of subscription receipts (each, a “Subscription Receipt”). Pursuant to an agency agreement dated October 3, 2025 (the “Agency Agreement“) between the Company and BMO Capital Markets, as agent (the “Agent“), the Company issued a total 76,666,667 Subscription Receipts at a price of $0.15 per Subscription Receipt for aggregate gross proceeds to the Company of $11,500,000 (the “Offering”), which included the exercise in full by the Agent of its over-allotment option granted pursuant to the Agency Agreement. The Subscription Receipts were created and issued pursuant to the terms of a subscription receipt agreement...

SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com. ABOUT MERIT Founded...